S-biomedic

S-Biomedic is a pioneering private biotech company developing live skin probiotics and postbiotics derived from the skin's most abundant bacterium, Cutibacterium acnes. The company's platform aims to treat conditions like acne by modulating the skin microbiome to restore its natural, healthy balance, moving beyond conventional dermatological treatments. It has validated its approach through over 15 clinical studies and has established a significant partnership with Beiersdorf, which recently acquired the company. S-Biomedic's first commercial program, Sencyr®, is a microbiome care system for acne-prone skin.

Proprietary Modulation Technology using native skin bacteria (Cutibacterium acnes) to develop Living Skin Probiotics and Postbiotics for restoring a healthy skin microbiome.

S-Biomedic competes in the emerging skin microbiome space with other biotechs like Azitra, MatriSys Bioscience, and Xycrobe, as well as cosmetic giants (L'Oréal, Unilever) developing microbiome-inspired products. Its key competitive advantage is its exclusive focus on and deep expertise in the native skin bacterium Cutibacterium acnes, and its strategic backing by Beiersdorf.